News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Etubics Will Present Results Of Its Colorectal Cancer Phase 1 And 2 Immunotherapy Trial At The Annual American Society of Clinical Oncology Meeting In Chicago



5/29/2014 7:04:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Etubics Corporation, a clinical stage biotechnology company with a proprietary platform technology that delivers a long lasting "active" immune response against diseases, will present clinical data from its Phase 1/2 proof of concept clinical trials using an immunotherapeutic to treat patients with metastatic colorectal cancer or mCRC at the Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago on Sunday, June 1st, 2014 during the Developmental Therapeutics Immunotherapy session from 8:00 a.m. to 11:45 a.m.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES